Acute treatment with the p110β-specific inhibitor TGX-221 reduced protein synthesis in FXS-patient-derived iPSCs, indicative of a higher PI3K activity and abnormal signaling in FXS patient neural cells [192]. The gene discussed is PIK3CD; the disease is fragile X syndrome.